MedPath

BAYER AG

BAYER AG logo
🇩🇪Germany
Ownership
Public
Established
1863-08-01
Employees
99.7K
Market Cap
$30.1B
Website
http://www.bayer.com
Clinical Trials
Related News

Evaluating the Efficacy Vardenafil 10 mg vs Tadalafil 10 mg in in Subjects With Erectile Dysfunction (ED)

Phase 4
Completed
Conditions
Erectile Dysfunction
Interventions
Drug: Levitra (Vardenafil, BAY38-9456)
Drug: Tadalafil
First Posted Date
2008-04-22
Last Posted Date
2013-10-11
Lead Sponsor
Bayer
Target Recruit Count
759
Registration Number
NCT00663130

A Phase IV Study of Cipro XR in Uncomplicated UTI

Phase 4
Completed
Conditions
Urinary Tract Infections
Interventions
Behavioral: Cipro XR (Ciprofloxacin, BAYQ3939)
First Posted Date
2008-04-22
Last Posted Date
2014-12-02
Lead Sponsor
Bayer
Target Recruit Count
7614
Registration Number
NCT00663806

A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC

Phase 2
Completed
Conditions
Carcinoma, Renal Cell
Interventions
Drug: Regorafenib (Stivarga, BAY73-4506)
First Posted Date
2008-04-22
Last Posted Date
2021-01-29
Lead Sponsor
Bayer
Target Recruit Count
49
Registration Number
NCT00664326

Assessment of Duration of Erection With Vardenafil 10 mg

Phase 4
Completed
Conditions
Erectile Dysfunction
Interventions
Drug: Placebo
Drug: Levitra (Vardenafil, BAY38-9456)
First Posted Date
2008-04-22
Last Posted Date
2014-12-30
Lead Sponsor
Bayer
Target Recruit Count
201
Registration Number
NCT00663728

Levitra® - Real Life Safety and Efficacy of Levitra

Phase 4
Completed
Conditions
Erectile Dysfunction
Interventions
Drug: Levitra (Vardenafil, BAY38-9456)
First Posted Date
2008-04-22
Last Posted Date
2014-12-19
Lead Sponsor
Bayer
Target Recruit Count
30825
Registration Number
NCT00663598

Evaluating of the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction

Phase 4
Completed
Conditions
Erectile Dysfunction
Interventions
Drug: Levitra (Vardenafil, BAY38-9456)
First Posted Date
2008-04-21
Last Posted Date
2009-06-22
Lead Sponsor
Bayer
Target Recruit Count
102
Registration Number
NCT00662441

Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec

Phase 2
Completed
Conditions
Chronic Myelogenous Leukemia
Interventions
Drug: Nexavar (Sorafenib, BAY43-9006)
First Posted Date
2008-04-18
Last Posted Date
2014-12-23
Lead Sponsor
Bayer
Target Recruit Count
10
Registration Number
NCT00661180

Depression Related Improvement With Vardenafil for Erectile Response

Phase 3
Completed
Conditions
Depression
Erectile Dysfunction
Interventions
Drug: Placebo
Drug: Levitra (Vardenafil, BAY38-9456)
First Posted Date
2008-04-18
Last Posted Date
2014-12-23
Lead Sponsor
Bayer
Target Recruit Count
280
Registration Number
NCT00661219

Assessment of Efficacy of Vardenafil, Influence on Self-esteem and Self-confidence in Subjects With Erectile Dysfunction

Phase 3
Completed
Conditions
Erectile Dysfunction
Interventions
Drug: Levitra (Vardenafil, BAY38-9456)
Drug: Placebo
First Posted Date
2008-04-18
Last Posted Date
2014-12-30
Lead Sponsor
Bayer
Target Recruit Count
129
Registration Number
NCT00661596

Evaluation of Efficacy and Safety of Vardenafil in Patients With Erectile Dysfunction and Type 1 Diabetes

Phase 4
Completed
Conditions
Erectile Dysfunction
Interventions
Drug: Placebo
Drug: Levitra (Vardenafil, BAY38-9456)
First Posted Date
2008-04-18
Last Posted Date
2014-12-11
Lead Sponsor
Bayer
Target Recruit Count
318
Registration Number
NCT00660998
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy